REPLIGEN CORP Amortization of Debt Issuance Costs and Discounts
REPLIGEN CORP (RGEN) reported Amortization of Debt Issuance Costs and Discounts of $8.83 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfFinancingCostsAndDiscounts · last filed 2026-07-29
- REPLIGEN CORP amortization of debt issuance costs and discounts for the quarter ending 2026-06-30 was $4.46M, a 8.30% increase year-over-year.
- REPLIGEN CORP amortization of debt issuance costs and discounts for the quarter ending 2026-03-31 was $4.37M, a 8.24% increase year-over-year.
- REPLIGEN CORP amortization of debt issuance costs and discounts for the quarter ending 2025-12-31 was $4.29M, a 8.23% increase year-over-year.
- REPLIGEN CORP amortization of debt issuance costs and discounts for the quarter ending 2025-09-30 was $4.20M.
- REPLIGEN CORP amortization of debt issuance costs and discounts for fiscal 2025 was $16.65M, a 6.79% increase from fiscal 2024.
- REPLIGEN CORP amortization of debt issuance costs and discounts for fiscal 2024 was $15.59M, a 536.76% increase from fiscal 2023.
- REPLIGEN CORP amortization of debt issuance costs and discounts for fiscal 2023 was $2.45M.
- REPLIGEN CORP amortization of debt issuance costs and discounts for fiscal 2020 was $10.97M, a 45.57% increase from fiscal 2019.
| Period end | Amortization of Debt Issuance Costs and Discounts 3 month | Amortization of Debt Issuance Costs and Discounts 6 month | Amortization of Debt Issuance Costs and Discounts 9 month | Amortization of Debt Issuance Costs and Discounts 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $8.83M 10-Q · filed 2026-07-29 | $13.12M derived: sum of 3 quarters · filed 2026-07-29 | $17.32M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $4.37M 10-Q · filed 2026-05-06 | $8.66M derived: sum of 2 quarters · filed 2026-05-06 | $12.86M derived: sum of 3 quarters · filed 2026-05-06 | $16.98M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $4.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $8.49M derived: sum of 2 quarters · filed 2026-02-26 | $12.61M derived: sum of 3 quarters · filed 2026-07-29 | $16.65M 10-K · filed 2026-02-26 |
| 2025-09-30 | $4.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $8.32M derived: sum of 2 quarters · filed 2026-07-29 | $12.36M 10-Q · filed 2025-11-04 | $16.32M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $4.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $8.16M 10-Q · filed 2026-07-29 | $12.12M derived: sum of 3 quarters · filed 2026-07-29 | |
| 2025-03-31 | $4.04M 10-Q · filed 2026-05-06 | $8.00M derived: sum of 2 quarters · filed 2026-05-06 | ||
| 2024-12-31 | $3.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $15.59M 10-K · filed 2026-02-26 | ||
| 2024-09-30 | $11.63M 10-Q · filed 2025-11-04 | |||
| 2023-12-31 | $2.45M 10-K · filed 2026-02-26 | |||
| 2020-12-31 | $10.97M 10-K · filed 2021-02-24 | |||
| 2019-12-31 | $7.54M 10-K · filed 2021-02-24 | |||
| 2018-12-31 | $4.25M 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |